Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 136


Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.

Allred DC.

J Natl Cancer Inst. 2010 May 5;102(9):585-7. doi: 10.1093/jnci/djq118. Epub 2010 Apr 28. No abstract available.


Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.


DCIS prognostic markers: a few new candidates emerge.

Nelson NJ.

J Natl Cancer Inst. 2010 May 5;102(9):588-90. doi: 10.1093/jnci/djq161. Epub 2010 Apr 28. No abstract available.


[Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].

Polgár C, Orosz Z, Kahán Z, Gábor G, Jani N, Cserni G, Hadijev J, Kulka J, Sulyok Z, Boross G, Lázár G, László Z, Diczházi C, Udvarhelyi N, Szabó E, Péntek Z, Major T, Fodor J.

Magy Onkol. 2008 Sep;52(3):269-77. doi: 10.1556/MOnkol.52.2008.3.4. Hungarian.


The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.

Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.

Cancer. 2004 Jun 1;100(11):2317-27.


Can some DCIS patients avoid adjuvant therapy? Still unknown.

Schmidt C.

J Natl Cancer Inst. 2011 Apr 6;103(7):530-1. doi: 10.1093/jnci/djr118. Epub 2011 Mar 23. No abstract available.


Luminal B breast tumors are not HER2 positive.

Bhargava R, Dabbs DJ.

Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26. No abstract available.


Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.

Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE.

Eur J Cancer. 2003 Mar;39(5):622-30.


Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

Wärnberg F, Nordgren H, Bergkvist L, Holmberg L.

Br J Cancer. 2001 Sep 14;85(6):869-74.


The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?

Tubbs RR, Stoler MH.

Mod Pathol. 2000 Jan;13(1):1-3. No abstract available.


Ductal carcinoma in situ, complexities and challenges.

Leonard GD, Swain SM.

J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. Review.


The certainties and the uncertainties of ductal carcinoma in situ.

Morrow M.

J Natl Cancer Inst. 2004 Mar 17;96(6):424-5. No abstract available.


Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.

Ballehaninna UK, Chamberlain RS.

J Clin Oncol. 2011 Feb 1;29(4):e97-8; author reply e99. doi: 10.1200/JCO.2010.32.6850. Epub 2010 Dec 20. No abstract available.


Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.

Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.

Pathol Int. 2003 Jul;53(7):422-8.


The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast.

Neuschatz AC, DiPetrillo T, Steinhoff M, Safaii H, Yunes M, Landa M, Chung M, Cady B, Wazer DE.

Cancer. 2002 Apr 1;94(7):1917-24.


Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.

Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C.

Am J Clin Pathol. 2001 May;115(5):709-18.


[The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999].

Schwartz GF, Solin LJ, Olivotto IA, Ernster VL; Consensus Conference Committee.

Bull Cancer. 2000 Jun;87(6):499-506. Review. French. No abstract available.


Mode of detection and secular time for ductal carcinoma in situ.

Pisano ED.

J Natl Cancer Inst Monogr. 2010;2010(41):142-4. doi: 10.1093/jncimonographs/lgq028. Review.


Molecular markers for the diagnosis and management of ductal carcinoma in situ.

Polyak K.

J Natl Cancer Inst Monogr. 2010;2010(41):210-3. doi: 10.1093/jncimonographs/lgq019. Review.


Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.

Virnig BA, Tuttle TM, Shamliyan T, Kane RL.

J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk